The two recent FDA drug approvals, Kalydeco (ivacaftor) and Keytruda (pembrolizumab), pertaining to 33 cystic fibrosis mutations and cancer treatment based on a genetic feature respectively, point to an encouraging future for precision medicine. National Cancer Institute (NCI) conducts NCI-COG Pediatric MATCH trial that enrolls children and adolescents by advanced cancer therapy based on their genetic abnormality, where NCI also plans to support new immunotherapy clinical trials, antibody, testing of new combinations of the cell, small molecule, and radiation therapy studies, which include sequencing of tumor specimens.

Request Sample Copy Of This Report: www.coherentmarketinsights.com/insight/request-sample/145

In July 2017, NCI has also launched various precision medicine trials, which include Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials (ALCHEMIST), Lung Cancer Master Protocol (Lung-MAP), Molecular Analysis for Therapy Choice (NCI-MATCH), and Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT).

The cost and time required for developing new precision medicines is expected to reduce due to the development of big data analysis and IT sector. Moreover, the development of new precision medicines will help in providing the right prescription to improve patient’s health. Huge amount of useful data required for tailored prescription is created by numerous genetic tests and diagnostic tests, which are to be carried out to provide precision medicines. Physicians are able to provide precision medicine, as big data analysis and IT are able to crunch, analyze, and store the necessary data.

Request for Customization of Research @ https://www.coherentmarketinsights.com/insight/request-customization/145

Key players in the market who are working towards developing bioinformatics technology for precision medicine research applications are funded by the government. For instance, in August 2017, Armonica Technologies, Inc., an Albuquerque-based company, received US$ 1.5 million as a catalyst fund. The drugs developed by manufacturers are hard to approve and expensive. They are not functional for large number of population, which has built the pressure on pharmaceutical companies to develop an active drug to cure the disease, which can be done with the help of Big Data Analysis and IT sectors to manufacture the precision medicines.

Growth restraining factors for precision medicine include unavailability of the insurance coverage on the genetic test, which is a mandatory test to analysis the mutation and according to it precision medicine could be provided. High cost of genetic test also hampers the growth of precision medicine market.

Key players in the precision medicine market are adopting strategies such as collaboration to strengthen their product portfolio. In 2016, Precision for Medicine, Inc. signed a deal for the acquisition of ACT Oncology, which will help the company to have a strong foothold in the personalized cancer clinical trial space. In August 2017, Variantyx, a genetic testing company, announced its partnership with FDNA. FDNA has a facial recognition software, which helped in the diagnosis of rare diseases. It is expected to fulfill the demand of patients and offer them precision medicine.

Make an inquiry for purchasing this report @ https://www.coherentmarketinsights.com/insight/buy-now/145

Some major players operating in the precision medicine market includes Intomics, ferrer incode, Nanostring Technologies, Inc.Tepnel Pharma Services, Pfizer, Inc., Novartis AG, Teva Pharmaceuticals, Merck & Co., Inc., Qiagen N.V., and Quest Diagnostics.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]